ArticleJournal of epidemiology2017
A population-based cohort study suggests an increased risk of multiple sclerosis incidence in patients with type 2 diabetes mellitus.
Article in Journal of epidemiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Diabetes mellitus and risk of multiple sclerosis: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Type 2 diabetes mellitus in people with multiple sclerosis: a systematic review and meta-analysis.Acta neurologica Belgica · 2026Review
- The promise of GLP-1 receptor agonists for neurodegenerative diseases.The Journal of clinical investigation · 2026Review
- Association Between T2DM, TyG Index, Multiple Sclerosis, and Rheumatoid Arthritis: Insights into Potential Mechanisms.Molecular neurobiology · 2025Article
- Associations Between Dietary Factors, Metabolic Factors, Sleep Disorders, Physical Activity, and the Risk of Multiple Sclerosis: A Univariable and Multivariable Mendelian Randomization Study.Food science & nutrition · 2025Article
- Incretin-based therapeutics for the treatment of neurodegenerative diseases.Nature metabolism · 2025Review
- Unmasking the Silent Threat: Prevalence of Cardiovascular Risk Factors in MS Patients in Bucharest, Romania.Journal of clinical medicine · 2025Article
- PEX11B palmitoylation couples peroxisomal dysfunction with Schwann cells fail in diabetic neuropathy.Journal of biomedical science · 2025Article
- Associations between tooth loss, denture use, and dementia in older Taiwanese adults.Journal of the Chinese Medical Association : JCMA · 2025Article
- Exploring the Impact of Social Media on Attaining HbA1c Targets in Individuals with Type 2 Diabetes Mellitus in Iraq: A Cross-Sectional Study.Clinical medicine insights. Endocrinology and diabetes · 2024Article
- The p66International journal of molecular sciences · 2023Review
- The Importance of Managing Modifiable Comorbidities in People with Multiple Sclerosis: A Narrative Review.Journal of personalized medicine · 2023Review
- Article
- Temporally ordered associations between type 2 diabetes and brain disorders - a Danish register-based cohort study.BMC psychiatry · 2022Article
- The prevalence of comorbidities in patients with multiple sclerosis: population-based registry data.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- Proposed minimal essential co-expression and physical interaction networks involved in the development of cognition impairment in human mid and late life.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- Risk of Psychiatric Disorders in Multiple Sclerosis: A Nationwide Cohort Study in an Asian Population.Neuropsychiatric disease and treatment · 2021Article
- Epidemiology of pediatric multiple sclerosis, neuromyelitis optica, and optic neuritis in Taiwan.Journal of neurology · 2020Article
- A Network-Based Bioinformatics Approach to Identify Molecular Biomarkers for Type 2 Diabetes that Are Linked to the Progression of Neurological Diseases.International journal of environmental research and public health · 2020Article
- Impact of delayed treatment on exacerbations of multiple sclerosis among Puerto Rican patients.Surgical neurology international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo prospectively investigate the incidence and relative risks of multiple sclerosis (MS) in patients with type 2 diabetes (T2DM). MATERIALS AND
methodsPatients with T2DM (n = 614,623) and age- and sex-matched controls (n = 614,021) were followed from 2000 to 2008 to identify cases of newly diagnosed MS (ICD-9-CM: 340). The person-year approach with Poisson assumption was used to evaluate the incidence density. We estimated the covariate-adjusted hazard ratio (HR) of MS incidence in relation to T2DM diabetes using a multiple Cox proportional hazard regression model.
resultsOver 9 years of follow-up, 175 T2DM patients were newly diagnosed with MS, and 114 matched controls had the same first-ever diagnosis, representing a covariate-adjusted HR of 1.44 (95% confidence interval [CI], 1.08-1.94). The sex-specific adjusted HR for both men and women with T2DM was also elevated at 1.34 (95% CI, 0.81-2.23) and 1.51 (95% CI, 1.05-2.19), respectively. Women aged ≤50 years had the greatest risk of MS (HR 2.16; 95% CI, 1.02-4.59).
conclusionThis study demonstrated a moderate but significant association of T2DM with MS incidence, and the association was not confounded by socio-demographic characteristics or certain MS-related co-morbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.